Abstract
Young women are particularly vulnerable for acquiring HIV yet they are often excluded from clinical trials testing new biomedical intervention. We assessed the HIV incidence and feasibility of enrolling a cohort of young women for potential participation in future clinical trials. Between March 2004 and May 2007, 594 HIV uninfected 14–30 year old women were enrolled into a longitudinal HIV risk reduction study in KwaZulu-Natal, South Africa. The overall HIV prevalence at screening in young girls below the age of 18 years was 27.6 % compared to 52.0 % in the women above 18 years, p < 0.001. HIV incidence was 4.7 [95 % Confidence interval (CI) 1.5–10.9) and 6.9 (95 % CI 4.8–9.6)/100 women years (wy), p = 0.42 and pregnancy rates were 23.7 (95 % CI 14.9–35.9) and 16.4 (95 % CI 12.9–20.6)/100 wy, p = 0.29, in the women below and above 18 years respectively. Retention was similar in both groups (71.0 vs. 71.5 %, p = 0.90). This study demonstrates that the inclusion of young girls between the ages of 14 and 17 years in longitudinal studies is feasible and their inclusion in clinical trials would maintain scientific integrity and power of the study.
Similar content being viewed by others
References
World Health Organisation and Joint United Nations Programme on HIV/AIDS. GLOBAL HIV/AIDS RESPONSE—epidemic update and health sector progress towards Universal Access. http://whqlibdoc.who.int/publications/2011/9789241502986_eng.pdf2011.
Gouws E, Stanecki KA, Lyerla R, Ghys PD. The epidemiology of HIV infection among young people aged 15–24 years in southern Africa. AIDS. 2008;22(Suppl 4):S5–16.
Gouws E. HIV incidence rates in South Africa. In: Abdool Karim S. S, Abdool Karim Q, editors. HIV/AIDS in South Africa. New York: Cambridge University Press; 2nd Edition. 2010. pp. 74–84.
Rehle T, Shisana O, Pillay V, Zuma K, Puren A, Parker W. National HIV incidence measures–new insights into the South African epidemic. S Afr Med J. 2007;97:194–9.
National Department of Health. The 2010 National Antenatal Sentinel HIV and Syphilis Prevalence Survey in South Africa. 2011.
Shisana O, Rehle T, Simbayi LC, Zuma K, Jooste S, Pillay-van-Wyk V, et al. South African national HIV prevalence, incidence, behaviour and communication survey 2008: A turning tide among teenagers?. Cape Town: HSRC Press; 2009.
Collins C, Coates TJ, Curran J. Moving beyond the alphabet soup of HIV prevention. AIDS. 2008;22(Suppl 2):S5–8.
Johnson BT, Scott-Sheldon LA, Huedo-Medina TB, Carey MP. Interventions to reduce sexual risk for human immunodeficiency virus in adolescents: a meta-analysis of trials, 1985–2008. Arch Pediatr Adolesc Med. 2011;165:77–84.
Abdool Karim Q, Kharsany AB, Frohlich JA, Werner L, Mashego M, Mlotshwa M, et al. Stabilizing HIV prevalence masks high HIV incidence rates amongst rural and urban women in KwaZulu-Natal, South Africa. Int J Epidemiol. 2011;40:922–30.
Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493–505.
Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99.
Centre for Disease Control Prevention. The CDC Botswana TDF-2 study: CDC trial and another major study find PrEP can reduce risk of HIV infection among heterosexuals. July 13, 2011. http://www.cdc.gov/nchhstp/newsroom/PrEPHeterosexuals.html. Accessed 20 Jan 2012.
Science News. Partners PrEP study: pivotal study in Africa finds that HIV medications prevent HIV infection. July 13, 2011. http://www.sciencedaily.com/releases/2011/07/110713092149.htm. Accessed 20 Jan 2012.
Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, LE Mansoor, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science. 2010;329:1168–74.
Early end for FEM-PrEP HIV prevention trial. AIDS Patient Care STDS 2011,25:383.
National Institute of Allergy and Infectious Diseases (NIAID). Clinical trial of antiretroviral-based HIV prevention strategies for women now under way. Sept. 16, 2009 http://www.niaid.nih.gov/news/newsreleases/2009/pages/voice.aspx. Accessed 20 Jan 2012.
Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, Grant R, Kashuba A, Crucitti T, Taylor D, and FEM-PrEP Study Group. The FEM-PrEP Trial of Emtricitabine/Tenofovir Disoproxil Fumarate (Truvada) among African Women. 19th Conference on Retroviruses and Opportunistic Infections March 5–8, 2012, Seattle, Washington:Abstract Number 32LB.
Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS. 2006;20:543–51.
DiClemente RJ, Ruiz MS, Sales JM. Barriers to adolescents’ participation in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S12–7.
Singh JA, Abdool Karim SS, Abdool Karim Q, Mlisana K, Williamson C, Gray C, et al. Enrolling adolescents in research on HIV and other sensitive issues: lessons from South Africa. PLoS Med. 2006;3:e180.
MacQueen KM, Karim QA. Practice brief: adolescents and HIV clinical trials: ethics, culture, and context. J Assoc Nurses AIDS Care. 2007;18:78–82.
Nelson RM, Lewis LL, Struble K, Wood SF. Ethical and regulatory considerations for the inclusion of adolescents in HIV biomedical prevention research. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S18–24.
Strode A, Slack C, Essack Z. Child consent in South African law: implications for researchers, service providers and policy-makers. S Afr Med J. 2011;101:604–6.
Strode A, Slack C, Mushariwa M. HIV vaccine research--South Africa’s ethical-legal framework and its ability to promote the welfare of trial participants. S Afr Med J. 2005;95:598–601.
Slack C, Strode A, Fleischer T, Gray G, Ranchod C. Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa. BMC Med Ethics. 2007;8:5.
Ethical issues in the NIMH Collaborative HIV/STD Prevention Trial. AIDS 2007,21 Suppl 2: S69–80.
Rennie. S, Sugarman. J, and the HPTN Ethics working group. HIV prevention trials network ethics guidance for research. 2009, Available at: http://www.hptn.org/web%20documents/EWG/HPTNEthicsGuidance020310.pdf. Accessed 2 May 2011.
South Africa department of social development. Commencement of certain sections of the Children’s Act, June 29 2007. Available at: http://www.info.gov.za/speeches/2007/07062915151003.htm. Accessed 2 May 2011.
Strode A, Slack C, Essack Z. Child consent in South African law: implications for researchers, service providers and policy-makers. S Afr Med J. 2010;100:247–9.
Mystakidou K, Panagiotou I, Katsaragakis S, Tsilika E, Parpa E. Ethical and practical challenges in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited countries. SAHARA J. 2009;6:46–57.
Acknowledgments
The authors sincerely acknowledge the participation of the women in the study, the site staff for the management of study participants, laboratory staff for the testing and archiving of samples and data management staff for management and quality assurance of data. A special thanks to members of the CAPRISA Community Research Support Groups at the Vulindlela and eThekwini Clinical Research Sites. Sincere thanks to Ms Cheryl Baxter for her critical review of the manuscript. CAPRISA was established as part of the Comprehensive International Program of Research on AIDS (CIPRA) and supported by the National Institute of Allergy and infectious Disease (NIAID), National Institutes of Health (NIH) and the US Department of Health and Human Services (DHHS) (grant# 1 U19 AI51794). The US President’s Emergency Plan for AIDS Relief (PEPfAR) Strategic Information grant for supporting the HIV counseling and testing programme. LIFElab, a biotechnology division of the South African Department of Science and Technology (DST) and Columbia University-Southern African Fogarty AIDS International Training and Research Programme (AITRP) funded by the Fogarty International Center, National Institutes of Health (grant# D43TW00231) for support of training for conduct of clinical trials.
Conflict of Interest
All authors declare that they have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Abdool Karim, Q., Kharsany, A.B.M., Frohlich, J.A. et al. HIV Incidence in Young Girls in KwaZulu-Natal, South Africa-Public Health Imperative for Their Inclusion in HIV Biomedical Intervention Trials. AIDS Behav 16, 1870–1876 (2012). https://doi.org/10.1007/s10461-012-0209-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-012-0209-y